Chong Kun Dang successful in patent challenge for Avodart

As successful in the patent challenge for the prostatic and alopecia treatment, ‘Avodart(dutasteride, GSK),’ Chong Kun Dang raised a chance to launch its follow-up drug on its own.

On the 11^th, the Intellectual Property Tribunal ruled Chong Kun Dang has not infringed on the patent right of the androstenone derivative(expired in 21 January 2016), the only registered patent of Avodart, by filing...